Skip to content
Checked.be
Complete company report
Generated 05-09-2026
Active BE 1013.285.655Private limited company

HEPHAISTOS-BELGIUM

Avenue de l'Hôpital 11 ·4000 Liège, Belgium· 1 yrs active
Sector: Research and development on biotechnology (72101)
Conclusion Checked

HEPHAISTOS-BELGIUM has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €219k and a net result of €-281k. Its solvency ranks better than 87% of 206 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.8% (low).

Based on the State Gazette, CBE and 1 annual account.
Key figures
Equity €219k
Net result €-281k
Staff (FTE) 1.7
Better than sector 87%
Financial profile 4 of 5 axes measured · computed by Checked
Health55Profitability0Solvency100Growth-Stability67
56 / 100

Mixed profile: strong on solvency, weaker on profitability.

Computed on 4 of 5 axes. Not measured: growth. An unmeasured axis is not a zero: no data was read for it.

Health 55
Profitability 0
Solvency 100
Growth -
Stability 67
Bankruptcy probability (12 mo) Checked model v1 · free
0.8% Low
0%0,5%1,5%4%10%≥25%

How do we compute this?

Risk Assessment rule-based
0 / 100
Low risk
Trust signals 2 signals
Young company
Founded in 2024, under 3 years, statistically higher risk.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags0 events
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score FY 2025 · computed
55 / 100 Fair
050100
Computed from 4 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€12k
estimate, not credit advice
Score components
Liquidity Current ratio 6.79 (≥ 1.5) +10
Quick ratio Quick ratio 6.79 (≥ 1.0) +5
Leverage Debt/equity 0.10 (< 1.0) +10
Profitability Negatieve ROE -128% -10
Interest coverage Interest coverage -115.3× (< 1.5×) -10
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview1 NBB filings
Annual accounts filed on 08-07-2026 with the NBB · fiscal year 2025 · abbreviated schema
Sector comparison
Fiscal year 2025 · NACE 72, Scientific research and development · compared within the same schema type (abbreviated schema)
Metric This company Sector median Position in the sector
Solvency 90.5% 48.9%
better than 87% of 206 sector peers
Net result €-281k €5k
better than 20% of 205 sector peers
Equity €219k €477k
better than 36% of 206 sector peers
Gross operating margin €-98k €89k
better than 13% of 184 sector peers
Staff costs €168k €515k
higher than 25% of 126 sector peers
Figures by fiscal year and ratios
Fiscal year2025
Depositabbreviated schema
Revenue-
EBITDA€-266k
Net profit€-281k
Cash flow€-269k
Staff costs€168k
Income taxes€540
Dividends-
Total assets€242k
Equity€219k
Debt€23k
of which ≤ 1y€23k
of which > 1y-
Working capital€133k
Employees (FTE)1.7
Ratios (computed)
2025
Current ratio6.79
Quick ratio6.79
Working capital ratio54.9%
Solvency90.5%
Debt / equity0.10
Long-term debt ratio-
Interest coverage-115.32
Gross margin-
Net margin-
ROA-115.9%
ROE-128.1%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts (22 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€242k
Fixed assets 21/28€84k
Formation expenses 20€3k
Tangible fixed assets 22/27€84k
Current assets 29/58€156k
Amounts receivable within one year 40/41€6k
Cash & bank 54/58€150k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€242k
Equity 10/15€219k
Contributions / capital 10/11€500k
Accumulated profits (losses) 14€-281k
Amounts payable 17/49€23k
Amounts payable within one year 42/48€23k
Trade debts payable within one year 44€1k
Income statement
Gross operating margin 9900€-98k
Operating result 9901€-278k
Financial income 75€0
Financial charges 65€2k
Result before taxes 9903€-280k
Income taxes 67/77€540
Net result for the period 9904€-281k
Result to be appropriated 9905€-281k
Legal Structure
NACE primary Research and development on biotechnology(72101)
Legal form Private limited company(610)
Incorporation06-09-2024
StatusActive
Postal code4000
Establishment units 1 location
HEPHAISTOS BELGIUM
Avenue de l'Hôpital 11, 4000 LiègeScientific research and development
since 20242.366.988.258
Real-estate footprint Source: CBE × cadastre
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
62826D0504/00R002
ProtectedMonument
 Wallonia 1.4 ha 1 · 2.3 ha 48.9 m · 8 fl.
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).
Updates 1 events
2026
08-07
NBB filing Annual accounts filed
fiscal year 2025 · abbreviated schema
NBB filing
Belgian State Gazette reading coverage 0 of 1 acts read

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Credit advice verdict per customer and amount
Company registry (CBE) Crossroads Bank
Activities
Research and development on biotechnology72101
Names & trade names
Legal nameFR HEPHAISTOS-BELGIUM
Similar companies Comparable size · 462 of 759 companies in this sector with filed accounts
BIOSILARIS BE 0550.879.529 · Huy
SUSTAINEER BE 0667.929.330 · Gent
PXLENCE BE 0597.690.838 · Gent
FENIXGM BE 0568.890.548 · Fleurus
NorthboundBio BE 1008.524.836 · Leuven
Source: Belgian State Gazette, CBE, NBB · generated via checked.be · indicative